SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is facing intense scrutiny and volatility following an earnings report that featured a double-beat but was overshadowed by weak sales outlooks and ongoing struggles in the Chinese market. The community is deeply polarized, with many investors debating whether the stock's multi-year lows represent a generational buying opportunity or evidence of a brand in long-term decline amidst stiff competition and political headwinds.

Tema ETF Trust - Tema Space Innovators ETF

Investors are actively debating the potential of the newly launched space-focused ETF, with many drawing comparisons to other high-volatility funds due to its significant exposure to companies like SpaceX. Sentiment is mixed as participants weigh the excitement over the sector's growth potential against questions regarding the fund's underlying structure and liquidity.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors monitor the company's transition into a commercial-stage biotech following the recent FDA approval of Yartemlea and a high-value partnership with Novo Nordisk. The community remains focused on the early commercial launch trajectory, upcoming milestone payments, and the stock's significant potential for rerating as institutional interest grows.

Ganymede

Investors are actively accumulating Ganymede, focusing on its stable structure and disciplined price action while debating the potential for a community-driven surge.

Maul Coin

Maul Coin is rapidly gaining attention as a community-driven project, with the retail base rallying around its active founder and the goal of hitting major market cap milestones. Investors are currently focused on the need for formal exchange charting and are actively encouraging one another to hold through volatility to prove the strength of the community.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending as investors react to the upcoming earnings release and intense speculation surrounding a potential acquisition, with the community actively debating whether a deal with a major industry player is imminent. While bulls are focused on the strategic value of the company's spectrum assets and recent partnership news, discussion remains heavily split between those anticipating a high-premium buyout and skeptics concerned about long-term valuation and past performance.

Blacksky Technology, Inc. is a space-based intelligence company, which engages in the business of delivering real-time imagery, analytics, and high-frequency monitoring of most critical and strategic locations, economic assets, and events. The firm is also involved in providing geospatial intelligence, imagery and related data analytic products and services, and mission systems that include the development, integration, and operation of satellite and ground systems to government and commercial customers. The company was founded in 2014 and is headquartered in Herndon, VA.

BlackSky Technology Inc - Ordinary Shares - Class A

BlackSky Technology is rallying following the announcement of a multi-year, $99 million sole-source government contract, a development community members view as a significant validation of its space-based intelligence tech stack. Investors are actively debating the company's long-term strategic positioning within the defense sector, with many pointing to the backlog growth and potential for future contract scaling as key drivers for long-term conviction.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Retail Wireless, and Broadband and Satellite Services. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Retail Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar is currently a focal point for investors seeking a strategic proxy for SpaceX, driven by its significant equity stake and ongoing spectrum deals with the rocket manufacturer. Market participants are actively discussing the stock's valuation relative to SpaceX's potential multi-trillion-dollar valuation, while closely monitoring institutional moves and the potential for a technical breakout.

Entrepreneurshares Series Trust - ERShares Private-Public Crossover ETF

Investors are flocking to XOVR as a rare, liquid vehicle for indirect exposure to SpaceX, sparking active debate over the fund's private valuation strategies compared to other space-focused assets. Community discussion is currently centered on the fund's portfolio structure, the potential for future SpaceX liquidity events, and comparisons with alternative investment vehicles like DXYZ and ARKVX.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals is trending after receiving FDA approval for Empaveli to treat rare kidney diseases, a catalyst that has bolstered sentiment regarding its expanded immunology portfolio. Investors are closely monitoring the company's commercial execution and ability to drive revenue growth as they balance these clinical milestones against ongoing discussions surrounding management's efficiency.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know

Shares of biopharmaceutical company iTeos Therapeutics, Inc. (ITOS) traded 20% higher on Wednesday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/28/3089457/0/en/iTeos-Therapeutics-Announces-Its-Intention-to-Wind-Down-Operations.html">announced</a> its intent to wind down operations and explore asset sales.iTeos said it decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value.The Board of Directors now intends to focus on leveraging the company’s cash balance to deliver near-term value to shareholders, including any proceeds from the potential sale of the company’s intellectual property and assets.iTeos ended the first quarter of 2025 with cash and investments of $624.3 million. Last month, the firm had said that it expects its cash balance to provide a runway through 2027.However, earlier this month, iTeos decided to <a href="https://stocktwits.com/news-articles/markets/equity/iteos-gsk-end-collaboration-on-experimental-cancer-therapy/chi8V5tRbZi">terminate</a> its collaboration with British pharmaceutical major GSK Plc for the development of experimental cancer therapy Belrestotug.The two companies were working together assessing the Belrestotug + Dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer.However, data from a Phase 2 study did not show improvements in progression-free survival with the combination compared to Dostarlimab monotherapy, and the companies subsequently decided to terminate the program and end the collaboration.iTeos CEO Michel Detheux had said the company is “truly disappointed” by the trial results and is taking “immediate steps” to preserve capital. &nbsp;On Stocktwits, retail sentiment around ITOS jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_28_at_11_05_44_AM_png_7ce0e324ab.webp" alt="ITOS's Sentiment Meter and Message Volume as of 11:05 a.m. ET on May 28, 2025 | Source: Stocktwits " width="626" height="67"><figcaption>ITOS's Sentiment Meter and Message Volume as of 11:05 a.m. ET on May 28, 2025 | Source: Stocktwits&nbsp;</figcaption></figure>A Stocktwits user expressed optimism about the company’s decision to halt operations.<stembedurl>https://stocktwits.com/BullDriven/message/616043049</stembedurl><a href="https://stocktwits.com/symbol/ITOS">ITOS stock </a>is up approximately 29% this year but down by more than 40% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/candel-therapeutics-gets-rmat-designation-for-prostate-cancer-therapy/ch0om35Rbs0">Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

iTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’

The company decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value after its collaboration with GSK plc ended. 

Equity

GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug

Shares of iTeos Therapeutics, Inc. (ITOS) rocketed 20% on Tuesday morning after the company announced it has decided to terminate its collaboration with British pharmaceutical major GSK Plc for the development of its experimental cancer therapy Belrestotug.The two companies were working together assessing the Belrestotug + Dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer.However, data from a Phase 2 study did not show improvements in progression-free survival with the combination compared to Dostarlimab monotherapy. Hence, the two companies have decided to end the collaboration and terminate the program.iTeos <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.iteostherapeutics.com/news-releases/news-release-details/iteos-reports-topline-interim-results-galaxies-lung-201-study">also</a> ended new enrollment for a phase 3 trial of the combination.GSK is communicating with investigators, institutional review boards, ethics committees, and health authorities about next steps for the appropriate management of currently enrolled patients, iTeos said.iTeos CEO Michel Detheux said the company is “truly disappointed” by the trial results. The firm is taking “immediate steps” to preserve capital and maximise shareholder value and has engaged TD Cowen to advise on the process.“...given current market conditions and our appreciation of the responsibility to our valued shareholders, we believe the best path forward is to promptly evaluate a full range of strategic alternatives to unlock the value of our assets,” Detheux said, while adding that the company has a strong balance sheet to enable it to pursue opportunities.On Stocktwits, retail sentiment around ITOS jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_13_at_9_51_08_AM_png_54cf65be0f.webp" alt="ITOS's Sentiment Meter and Message Volume as of 9:45 a.m. ET on May 13, 2025 | Source: Stocktwits" width="627" height="62"><figcaption>ITOS's Sentiment Meter and Message Volume as of 9:45 a.m. ET on May 13, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/ITOS">ITOS stock</a> is up by about 5% this year but has declined by about 52% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/vehicle-prices-rose-in-april-after-trump-tariffs/chi8mIbRbZg">Cadillac, Tesla, GMC Vehicles Get More Expensive In April After Trump Tariffs, Shows Data</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish

The two companies worked together to assess the Belrestotug + Dostarlimab doublet in treating a specific type of lung cancer.

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

ITeos Therapeutics Inc

Sprott Silver Miners & Physical Silver ETF ($SLVR)

Tradr 2x Long Innovation 100 Monthly ($MQQQ)

GraniteShares Autocallable NVDA ETF ($ANV)

Direxion Daily ASML Bull 2x ($ASMU)

The ultimate tool for the active trader. This award goes to the fund that helped traders master the market—whether by protecting against risks or jumping on the latest trends to capture quick wins.

ITOS
ITeos Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ITOS News

ITOSITeos Therapeutics Inc